# Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

> **NCT05481658** · PHASE1 · RECRUITING · sponsor: **Nicholas Gulati** · enrollment: 100 (estimated)

## Conditions studied

- Cutaneous Metastases

## Interventions

- **DRUG:** Diphencyprone (DPCP)

## Key facts

- **NCT ID:** NCT05481658
- **Lead sponsor:** Nicholas Gulati
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-06
- **Primary completion:** 2029-12
- **Final completion:** 2030-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05481658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05481658, "Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05481658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*